Amedisys Reports Fourth Quarter and Year-End 2022 Financial Results, Issues 2023 Guidance, Announces Sale of Its Personal Care Line of Business and Signs Innovative Palliative Care at Home Partnership

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. DFTX
9. HOOD
10. IBM

Go back to Amedisys Reports Fourth Quarter and Year-End 2022 Financial Results, Issues 2023 Guidance, Announces Sale of Its Personal Care Line of Business and Signs Innovative Palliative Care at Home Partnership

Amedisys (AMED) Tops Q4 EPS by 18c; Issues FY23 Guidance

February 15, 2023 4:21 PM EST

Amedisys (NASDAQ: AMED) reported Q4 EPS of $1.16, $0.18 better than the analyst estimate of $0.98. Revenue for the quarter came in at $562 million versus the consensus estimate of $560.59 million.

GUIDANCE:

Amedisys sees FY2023 EPS of $4.13-$4.36, versus the consensus of $4.86. Amedisys sees... More